Lenalidomide in the treatment of multiple myeloma: a review
Article Properties
-
LanguageEnglish
-
DOI (url)
-
Publication Date2008/06/01
-
Indian UGC (journal)
-
Refrences45
-
Citations59
-
X. Armoiry
-
G. Aulagner
-
T. Facon
Cite
Armoiry, X., et al. “Lenalidomide in the Treatment of Multiple Myeloma: A Review”. Journal of Clinical Pharmacy and Therapeutics, vol. 33, no. 3, 2008, pp. 219-26, https://doi.org/10.1111/j.1365-2710.2008.00920.x.
Armoiry, X., Aulagner, G., & Facon, T. (2008). Lenalidomide in the treatment of multiple myeloma: a review. Journal of Clinical Pharmacy and Therapeutics, 33(3), 219-226. https://doi.org/10.1111/j.1365-2710.2008.00920.x
Armoiry X, Aulagner G, Facon T. Lenalidomide in the treatment of multiple myeloma: a review. Journal of Clinical Pharmacy and Therapeutics. 2008;33(3):219-26.
Journal Categories
Medicine
Public aspects of medicine
Toxicology
Poisons
Medicine
Therapeutics
Pharmacology
You May Also Like
- A Bayesian neural network method for adverse drug reaction signal generation
- Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939—an oral, direct Factor Xa inhibitor—after multiple dosing in healthy male subjects
- Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction
- Clinical consequences of polypharmacy in elderly
- Long-term side effects of glucocorticoids
Refrences
| Title | Journal | Journal Categories | Citations | Publication Date |
|---|---|---|---|---|
Phase III trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4A03): A trial coordinated by the Eastern Cooperative Oncology Group | Journal of Clinical Oncology |
| 32 | 2007 |
Lenalidomide plus high-dose dexamethasone provides improved overall survival compared to high-dose dexamethasone alone for relapsed or refractory multiple myeloma (MM): Results of a North American phase III study (MM-009) | Journal of Clinical Oncology |
| 37 | 2006 |
| Long-term Results of Response to Therapy, Time to Progression, and Survival With Lenalidomide Plus Dexamethasone in Newly Diagnosed Myeloma | Mayo Clinic Proceedings |
| 114 | 2007 |
| 10.1182/blood.V106.11.449.449 | 2005 | |||
| Multiple Myeloma: Diagnosis and Treatment | Mayo Clinic Proceedings |
| 154 | 2005 |
Citations
| Title | Journal | Journal Categories | Citations | Publication Date |
|---|---|---|---|---|
| Al/ZnO nanoparticle as an effective nanocarrier in delivery of lenalidomide anti-multiple myeloma cancer drug | Materials Technology |
| 2024 | |
| Cancer drugs with high repositioning potential for Alzheimer’s disease | Expert Opinion on Emerging Drugs |
| 2023 | |
Introduction to small molecule drug discovery and preclinical development | Frontiers in Drug Discovery |
| 2023 | |
Understanding the Immunopathology of HTLV-1-Associated Adult T-Cell Leukemia/Lymphoma: A Comprehensive Review | Biomolecules |
| 2023 | |
Novel Oleanolic Acid-Phtalimidines Tethered 1,2,3 Triazole Hybrids as Promising Antibacterial Agents: Design, Synthesis, In Vitro Experiments and In Silico Docking Studies | Molecules |
| 2 | 2023 |
Citations Analysis
The category
Science: Chemistry 30
is the most commonly referenced area in studies that cite this article. The first research to cite this article was titled Current Awareness in Hematological Oncology and was published in 2008. The most recent citation comes from a 2024 study titled Al/ZnO nanoparticle as an effective nanocarrier in delivery of lenalidomide anti-multiple myeloma cancer drug. This article reached its peak citation in 2022, with 7 citations. It has been cited in 47 different journals, 19% of which are open access. Among related journals, the The Journal of Organic Chemistry cited this research the most, with 4 citations. The chart below illustrates the annual citation trends for this article.